Monoclonal antibody reactive with a novel hla determinant on mhc class i molecules and method for activating lymphocytes
CA 2038397 A1 · Owner: Bristol-Myers Squibb Company · Inventors: Mittler, Robert S.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to novel monoclonal antibody 4-10 produced by hybridoma ATCC No. HB10355 and its use in the activation of lymphocytes, particularly T cells. Monoclonal antibody 4-10 activates T cells without requiring co-stimulatory agents. The antibody, methods and compositions of this invention are useful in the activation of lymphocytes and in treating immune diseases. 6988APL.2
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 15, 1991. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended March 15, 2011.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 15, 2013.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.